Evoke Pharma, Inc. Announces Closing of Initial Public Offering of 2,100,000 Shares of Common Stock

Published: Oct 01, 2013

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

SAN DIEGO, Sept. 30, 2013 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced the closing of its previously announced initial public offering of common stock. The Company sold a total of 2,100,000 shares of its common stock, at an initial public offering price of $12.00 per share. The gross proceeds to Evoke Pharma from the initial public offering were $25,200,000, before underwriting discounts and commissions and estimated offering expenses. Evoke Pharma has granted the representative of the underwriters a 30 day option to purchase up to 315,000 additional shares of common stock from the Company to cover over-allotments, if any.

Help employers find you! Check out all the jobs and post your resume.

Back to news